Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Satellos Bioscience ( (TSE:MSCL) ) just unveiled an announcement.
Satellos Bioscience has completed enrollment for its Phase 1b trial of SAT-3247 in adult patients with Duchenne muscular dystrophy, with data expected in Q2 2025. The company has secured regulatory approval for a long-term follow-up study and plans to initiate a Phase 2 trial in pediatric patients. Financially, Satellos reported a net loss of $6.1 million for Q1 2025, with $41.2 million in funds available to support its operations and upcoming trials.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on TSE:MSCL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.
Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.
To see Spark’s full report on TSE:MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing medicines to treat degenerative muscle diseases. The company is advancing its novel drug, SAT-3247, targeting Duchenne muscular dystrophy (DMD) and is positioned to conduct further clinical trials to assess its efficacy and safety.
Average Trading Volume: 149,363
Technical Sentiment Signal: Sell
Current Market Cap: C$98.16M
See more insights into MSCL stock on TipRanks’ Stock Analysis page.